Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

被引:68
作者
Iravani, Mahmoud M. [1 ]
Jenner, Peter [1 ]
机构
[1] Kings Coll London, Sch Biomed Sci, Inst Pharmaceut Sci, Neurodegenerat Dis Res Ctr, London WC2R 2LS, England
关键词
Levodopa; Parkinson's disease; Dyskinesia; Presynaptic mechanisms; Postsynaptic mechanisms; DOPA-INDUCED DYSKINESIA; NITRIC-OXIDE SYNTHASE; METABOTROPIC GLUTAMATE RECEPTORS; INDUCED MOTOR COMPLICATIONS; CANNABINOID CB1 RECEPTOR; ADENOSINE A(2A) RECEPTORS; MESSENGER-RNA EXPRESSION; MODULATE ACETYLCHOLINE-RELEASE; ABNORMAL INVOLUNTARY MOVEMENTS; IDIOPATHIC PARKINSONS-DISEASE;
D O I
10.1007/s00702-011-0698-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A significant proportion of patients with Parkinson's disease (PD) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment. Dyskinesia can only be effectively treated by a reduction in drug dose, which limits efficacy, by co-administration of the weak NMDA antagonist amantadine or by surgical treatment (pallidotomy, DBS). This raises the important question of why dyskinesia occurs in PD and how it can be avoided or suppressed by pharmacological treatment. This review assesses some of the mechanisms that underlie dyskinesia induction and expression from presynaptic changes in dopaminergic neurones to postsynaptic alterations in basal ganglia function and examines potential approaches to prevention and treatment. These include glutamatergic approaches where agents that directly or indirectly alter glutamatergic neurotransmission modify the intracellular influx of Ca2+ and reduce the formation of nitric oxide by neuronal nitric oxide synthase that may form an integral component of the complex cascade of events leading to dyskinesia. There is increasing evidence for the role of serotoninergic neurones in dyskinesia induction related to non-physiological formation and release of dopamine and serotoninergic agonists can modify dyskinesia expression. Similarly, noradrenergic receptors may serve to alter dyskinesia intensity and alpha-2-adrenoceptor antagonists alter the expression of levodopa-induced dyskinesia in both experimental models of PD and in man. Finally, other potential approaches to dyskinesia treatment based on manipulation of opiate, cannabinoid, adenosine and histamine receptors are considered. The conclusion is that the cause of levodopa-induced dyskinesia remains to be fully elucidated and that new approaches to treatment through non-dopaminergic mechanisms are required to control the onset and expression of involuntary movements.
引用
收藏
页码:1661 / 1690
页数:30
相关论文
共 443 条
[1]   Medical treatment of later-stage motor problems of Parkinson disease [J].
Ahlskog, JE .
MAYO CLINIC PROCEEDINGS, 1999, 74 (12) :1239-1254
[2]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[3]   CHANGES IN BRAIN DOPAMINE-RECEPTORS IN MPTP PARKINSONIAN MONKEYS FOLLOWING L-DOPA TREATMENT [J].
ALEXANDER, GM ;
SCHWARTZMAN, RJ ;
GROTHUSEN, JR ;
BRAINARD, L ;
GORDON, SW .
BRAIN RESEARCH, 1993, 625 (02) :276-282
[4]   Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons [J].
Andersson, M ;
Usiello, A ;
Borgkvist, A ;
Pozzi, L ;
Dominguez, C ;
Fienberg, AA ;
Svenningsson, P ;
Fredholm, BB ;
Borrelli, E ;
Greengard, P ;
Fisone, G .
JOURNAL OF NEUROSCIENCE, 2005, 25 (37) :8432-8438
[5]   Distribution and modulation of histamine H3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease [J].
Anichtchik, OV ;
Peitsaro, N ;
Rinne, JO ;
Kalimo, H ;
Panula, P .
NEUROBIOLOGY OF DISEASE, 2001, 8 (04) :707-716
[6]   Continuous dopaminergic delivery in Parkinson's disease [J].
Antonini, Angelo ;
Ursino, Giulia ;
Calandrella, Daniela ;
Bernardi, Laura ;
Plebani, Mauro .
JOURNAL OF NEUROLOGY, 2010, 257 :S305-S308
[7]   Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease [J].
Antonini, Angelo ;
Odin, Per .
PARKINSONISM & RELATED DISORDERS, 2009, 15 :S97-S100
[8]   Metabotropic glutamate receptors: electrophysiological properties and role in plasticity [J].
Anwyl, R .
BRAIN RESEARCH REVIEWS, 1999, 29 (01) :83-120
[9]   Metabotropic glutamate receptor-dependent long-term potentiation [J].
Anwyl, R. .
NEUROPHARMACOLOGY, 2009, 56 (04) :735-740
[10]   IMMUNOHISTOCHEMICAL EVIDENCE THAT CENTRAL SEROTONIN NEURONS PRODUCE DOPAMINE FROM EXOGENOUS L-DOPA IN THE RAT, WITH REFERENCE TO THE INVOLVEMENT OF AROMATIC L-AMINO-ACID DECARBOXYLASE [J].
ARAI, R ;
KARASAWA, N ;
GEFFARD, M ;
NAGATSU, T ;
NAGATSU, I .
BRAIN RESEARCH, 1994, 667 (02) :295-299